Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  GenSight Biologics S.A.    SIGHT   FR0013183985

GENSIGHT BIOLOGICS S.A.

(SIGHT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

GenSight Biologics S A : successfully raises €25 million in an oversubscribed private placement with US and European institutional investors

10/22/2020 | 01:15am EST

The following information is not intended for, and may not be accessed by, or distributed or disseminated to, persons resident or physically present in the United States of America (including its territories, the 'United States'), Canada, Japan or Australia, and does not constitute an offer to sell or the solicitation of an offer to purchase or acquire, any securities in the United States, Canada, Japan or Australia. Any offers described on the website are not being made and will not be made directly or indirectly in or into, or by use of the mails of, or by any means or instrumentality of interstate or foreign commerce of, or any facility of a national securities exchange of, the United States. All persons residing outside of the United States, Canada, Japan and Australia who wish to access the documents contained on this website should first ensure that they are not subject to local laws or regulations that prohibit or restrict their right to access this website, or require registration or approval for any acquisition or sale of securities by them. GenSight Biologics S.A. assumes no responsibility if there is a violation of applicable law and regulations by any person.

I certify that I am not a resident of or physically present in the United States, Canada, Japan or Australia.

I have read and understood the foregoing, and hereby make the certifications above and agree to comply with all of the above restrictions:

Disclaimer

Gensight Biologics SA published this content on 22 October 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 October 2020 05:14:05 UTC


© Publicnow 2020
All news about GENSIGHT BIOLOGICS S.A.
11/04GENSIGHT BIOLOGICS S A : reports validation of LUMEVOQ Marketing Authorisation A..
AQ
11/03GENSIGHT BIOLOGICS S A : reports validation of LUMEVOQ® Marketing Authorisation ..
PU
11/03GENSIGHT BIOLOGICS : Reports Validation of LUMEVOQ® Marketing Authorisation Appl..
BU
10/23GENSIGHT BIOLOGICS S A : successfully raises EUR25 million in an oversubscribed ..
AQ
10/22GENSIGHT BIOLOGICS S A : Securities Note
PU
10/22GENSIGHT BIOLOGICS S A : Amendment to the 2019 Universal Registration Document
PU
10/22GENSIGHT BIOLOGICS S A : launches a capital increase of approximately EUR25 mill..
AQ
10/22GENSIGHT BIOLOGICS S A : successfully raises €25 million in an oversubscribed pr..
PU
10/22GENSIGHT BIOLOGICS S A : Successfully Raises €25 Million in an Oversubscribed Pr..
BU
10/21GENSIGHT BIOLOGICS S A : launches a capital increase of approximately €25 millio..
PU
More news
Financials
Sales 2020 12,5 M 14,8 M 14,8 M
Net income 2020 -16,7 M -19,8 M -19,8 M
Net cash 2020 16,7 M 19,9 M 19,9 M
P/E ratio 2020 -9,42x
Yield 2020 -
Capitalization 221 M 263 M 263 M
EV / Sales 2020 16,4x
EV / Sales 2021 14,5x
Nbr of Employees 25
Free-Float 95,4%
Chart GENSIGHT BIOLOGICS S.A.
Duration : Period :
GenSight Biologics S.A. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GENSIGHT BIOLOGICS S.A.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 10,23 €
Last Close Price 5,59 €
Spread / Highest target 150%
Spread / Average Target 83,1%
Spread / Lowest Target 19,9%
EPS Revisions
Managers
NameTitle
Bernard Jacques Alex Gilly Chief Executive Officer & Director
Michael S. Wyzga Chairman
Thomas Gidoin Chief Financial Officer
Magali Taiel Chief Medical Officer
José-Alain Sahel Director
Sector and Competitors
1st jan.Capitalization (M$)
GENSIGHT BIOLOGICS S.A.124.95%263
GILEAD SCIENCES, INC.-7.28%75 525
VERTEX PHARMACEUTICALS-1.12%56 298
REGENERON PHARMACEUTICALS34.79%53 416
WUXI APPTEC CO., LTD.59.64%38 761
BIONTECH SE200.68%24 529